Pembrolizumab-associated hemophagocytic lymphohistiocytosis in recurrent metastatic squamous cell carcinoma of the ovary arising in a teratoma

Background: The expanding use of immune checkpoint inhibitors (ICIs) in gynecologic oncology has been accompanied by an increasing incidence of immune related adverse events (irAEs), requiring rapid recognition and management to prevent significant morbidity and mortality (Conroy and Naidoo, 2022; L...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Jenna S. Powers, Olivia W. Foley, Connor C. Wang, Jenna Marcus, Emily Hinchcliff
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Elsevier 2026-04-01
סדרה:	Gynecologic Oncology Reports
נושאים:	Hemophagocytic lymphohistiocytosis Immune checkpoint inhibitor Pembrolizumab Ovarian squamous cell carcinoma Immune-related adverse events
גישה מקוונת:	http://www.sciencedirect.com/science/article/pii/S2352578926000391
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!